Dr. Bellmunt on JAVELIN Bladder 100 data for maintenance avelumab in urothelial carcinoma

The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma.

Joaquim Bellmunt, MD, PhD, discusses the latest update on the phase 3 JAVELIN Bladder 100 trial (NCT02603432), in which frontline maintenance avelumab (Bavencio) and best supportive care (BSC) significantly prolonged overall survival vs BSC alone in patients with advanced urothelial carcinoma who had not progressed with first-line platinum-containing chemotherapy.

The initial results from JAVELIN Bladder 100 supported the FDA approval of avelumab for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma that has not progressed with first-line platinum-containing chemotherapy.

Bellmunt is associate professor of medicine at Harvard Medical School and director of the Bladder Cancer Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts.